Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2016 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Ohio State University
University of Texas
Washington University School of Medicine
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01862315
First received: May 20, 2013
Last updated: February 3, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2017
  Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)